Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease.
II. Assess the safety of von Willebrand factor in these patients.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004667
|Study Chair:||Gilbert C. White||University of North Carolina|